Press / media

The theme of Science Year 2026 is “Medicine of the Future.” At MS Wissenschaft, the floating science center touring Germany and Austria from May 7 to September 30, this year’s focus is on how researchers are already developing the medicine of tomorrow.

PerioTrap Pharmaceuticals GmbH received the VORSPRUNG Business Prize on May 5. The Fraunhofer IZI spin-off develops microbiome-based solutions for the prevention of gum disease.

Kytopen, T-CURX, and the Fraunhofer Institute for Cell Therapy and Immunology IZI establish a Center of Excellence to develop advanced, non-viral cell therapies. The Center of Excellence will serve as a hub for innovation in non-viral cell therapy development, focusing on scalable, efficient, and clinically robust manufacturing processes.

As part of the recently concluded strategic partnership between the Fraunhofer Institute for Cell Therapy and Immunology IZI and PlasmidFactory GmbH, the Fresenius-led EASYGEN consortium is appearing as a cooperation partner for the first time. The goal of EASYGEN is to establish a faster, more efficient, and virus-free manufacturing process for CAR-T cells directly at the patients' treatment site. For this purpose, the consortium partners will, among other things, utilize the minicircle technology of PlasmidFactory GmbH.